MARIETTA, Ga., April 24, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today Company's participation in the European Wound Management Association ("EWMA") 2017 Conference to be held in Amsterdam, The Netherlands from May 3 through May 5, 2017.
The 2017 EWMA Conference is EWMA's 27th annual conference offering high-level scientific presentations, knowledge and best practices exchange, and presentation of the most recent advances in wound management research and treatment. With up to 5,000 attendees, the EWMA is one of the largest and most prestigious wound management conferences in the world.
MiMedx will sponsor a Symposium entitled, "The Dynamic Impact of EpiFix® Dehydrated Human Amnion/Chorion Membrane Allograft – Defining the New Standard for Bioactive Healing" on May 4, 2017 from 16:00 to 17:00. Severin Läuchli, MD, will chair the symposium and Matthew Garoufalis, DPM, FASPS, FACFAOM, CWS, will be a symposium speaker. This symposium will detail published peer-reviewed clinical data, clinical case examples, and intriguing scientific evidence supporting the use of EpiFix for the treatment for acute and chronic wounds.
Symposium Chair Dr. Läuchli is the Chief of Dermatologic Surgery/Mohs Surgery and Wound Care and Assistant Professor, Department of Dermatology at the University Hospital, Zurich, Switzerland, and the President of the EWMA. Dr. Läuchli will present "The Swiss Experience with EpiFix." Physician and study author, Dr. Garoufalis is also the President of the International Federation of Podiatrists. Dr. Garoufalis will present "Application Techniques and Therapeutic Approached Using EpiFix Amniotic Allografts for Wound Healing and Surgical Procedures."
Parker H. "Pete" Petit, CEO, said, "We are honored to be associated with the EWMA and participate in their outstanding conference. The EWMA is focused on investigating the barriers to and possibilities of advanced therapies in the next generation of wound management. They also have a key focus on the prevention and management of surgical site infections. Their focus is well aligned with our strategies and priorities, and we are proud to be associated with the EWMA. Our significant participation at this year's EWMA Conference is part of our ongoing strategy to expand our presence in the international wound care markets and globally market our dHACM allografts."
Bill Taylor, President and COO, commented, "The EWMA conducts its activities in coordination with various national and international organizations aimed at goals such as increased data collection and quality of evidence, implementation of knowledge, and development of education within wound management. We share these goals in our pursuit of advances in the treatment and healing of acute and chronic wounds. We are excited to work with the EWMA in improving the delivery and availability of advance wound care therapies internationally."
MiMedx will provide in-booth education during the following times:
- May 3 from 10:30 to 18:00;
- May 4 from 9:00 to 16:30; and
- May 5 from 9:00 to 14:30.
Throughout the conference, MiMedx will be located at Booth #3 C 06.
MiMedx® is an integrated developer, processor and marketer of patent protected and proprietary regenerative and therapeutic biopharmaceutical products processed from donated placental tissues. "Innovations in Regenerative Medicine" is the framework behind our mission to give physicians products and tissues to help the body heal itself. We process the human placental tissue utilizing our proprietary PURION® Process among other processes, to produce safe and effective allografts. MiMedx proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. MiMedx is the leading supplier of placental tissue, having supplied over 800,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare.
Safe Harbor Statement
This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes. Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current information and belief, and are not guarantees of future performance. Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include the risk factors detailed from time to time in the Company's periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2016. By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company's disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.
SOURCE MiMedx Group, Inc.